The study, led by Kaiyuan Cen of Guidong People’s Hospital of Guangxi Zhuang Autonomous Region and Zhuoqiao He of the First Affiliated Hospital of Shantou University Medical College, was a single-centre retrospective cohort study of adults hospitalized with chronic heart failure between 31 May 2023 and 31 May 2024, with follow-up data locked on 31 May 2025. Of 201 patients screened, 160 met the inclusion criteria, and the clinical stakes of the exercise were immediately apparent: 68 of those 160 patients—42.5 per cent—experienced a major adverse cardiovascular event, or MACE, within a year of their index hospitalization. That figure underscores a persistent problem in cardiology. Chronic heart failure remains a condition of high and unevenly distributed risk, and the field has long lacked tools that can reliably separate the patient who will be readmitted or die within months from the one who will remain stable on guideline-directed therapy.

The technical core of the new approach lies in the transformation of the conventional 12-lead ECG into a vectorcardiogram using the Kors method, a well-established mathematical technique that reconstructs the heart’s electrical dipole as a rotating vector in three-dimensional space. Rather than viewing the heart’s depolarization and repolarization through the fixed projections of twelve surface electrodes, the vectorcardiogram traces the path of the cardiac electrical axis as a loop in the frontal, horizontal, and sagittal planes. From this reconstruction, the researchers extracted features that are difficult or impossible to appreciate on a standard tracing: the spatial angles between the QRS complex, which represents ventricular depolarization, and the T wave, which represents repolarization. Discordance between these two processes—measured as a wide QRS–T angle in any plane—is thought to reflect abnormal ventricular conduction and repolarization heterogeneity, electrophysiological substrate that has been linked in prior studies to arrhythmic death and adverse remodelling.

The prespecified primary model was deliberately parsimonious, incorporating just six predictors: left ventricular end-diastolic diameter (LVEDD) measured by echocardiography, New York Heart Association functional class, the frontal, horizontal, and sagittal QRS–T angles, and a binary morphological feature known as the QRS-loop reversal/U-turn sign. The latter is a qualitative abnormality in which the ventricular depolarization loop reverses its direction of rotation or executes a U-shaped turn, signalling aberrant conduction pathways. Notably, the investigators evaluated whether two of the most celebrated markers in heart failure prognostication—brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF)—added value beyond the six-predictor set, embedding them in full-model, comparator-model, and incremental-value analyses. Because the prediction target was a fixed 12-month probability rather than a time-to-event hazard, the team used multivariable logistic regression as the primary modelling framework, an appropriate choice for a binary endpoint observed over a uniform window.

The performance figures reported in the paper are striking. The six-predictor model produced an apparent AUC of 0.946, with a 95 per cent confidence interval of 0.914 to 0.978. Recognizing that apparent performance on the development dataset invariably overstates true predictive ability, the researchers subjected the model to bootstrap internal validation using 1,000 resamples. This procedure yielded an AUC optimism estimate of just 0.012, leaving an optimism-corrected AUC of 0.934. Calibration was assessed with equal rigour: the apparent Brier score of 0.091 rose modestly to 0.106 after bootstrap correction, calibration-in-the-large was −0.009, and the calibration slope was corrected from a perfect 1.000 to 0.852, with the same uniform shrinkage factor applied to the model’s coefficients to guard against overfitting in future applications. A shrinking factor of 0.852 means each predictor’s coefficient is tempered by roughly fifteen per cent, a standard penalty that trades a small loss in apparent fit for improved generalizability.

Perhaps the most clinically persuasive result came from the incremental-value analyses. When the VCG-derived features were added to a conventional base model built on standard clinical predictors, the AUC rose from 0.890 to 0.955—a difference of 0.065 that reached statistical significance at DeLong P = 0.001. The augmented model also achieved a lower Brier score and favourable discrimination and reclassification indices, indicating that it did not merely rank patients differently but genuinely moved them into more accurate risk categories. Decision-curve analysis, a method that evaluates the net clinical benefit of a model across a range of risk thresholds, suggested that the VCG-augmented approach would deliver higher net benefit than selected single-marker comparators within the development cohort. In practical terms, this means that at most clinically meaningful threshold probabilities, acting on the model’s predictions would identify more true events and generate fewer false alarms than relying on any single conventional marker alone.

The biological rationale for why these VCG features carry such prognostic weight is grounded in decades of electrophysiological research. Prior work has demonstrated that a wide spatial QRS–T angle predicts cardiac death in the general population, that the frontal QRS–T angle predicts increased morbidity and mortality in chronic heart failure, and that vectorcardiographic findings are associated with recurrent ventricular arrhythmias in patients with implantable cardioverter-defibrillators. The QRS–T angle quantifies the degree of spatial discordance between the sequence of ventricular activation and the sequence of recovery—discordance that widens as conduction disease, ischaemia, and structural remodelling accumulate in the failing myocardium. The QRS-loop reversal/U-turn sign adds morphological information about the activation pathway itself, capturing abnormalities such as conduction delay and scar-related altered depolarization that angle measures alone may miss. Together with echocardiographic ventricular dimensions and symptomatic status, these features sketch a compact portrait of both the structure and the electrophysiology of the failing heart.

The authors are careful, appropriately so, to frame the work as a development and internal validation study rather than a demonstration of clinical readiness. Internal validation by bootstrap quantifies how much a model’s apparent performance is inflated by overfitting to its own data, but it cannot address the questions that matter most before deployment: whether the model generalizes to patients from different hospitals, ethnic backgrounds, and health systems; whether ECG acquisition and processing pipelines elsewhere would yield comparable VCG reconstructions; and whether clinicians acting on the model’s outputs would genuinely alter management in ways that improve outcomes. The de-identified analytic dataset cannot be made publicly available owing to institutional privacy requirements, though statistical code and data excerpts are available from the corresponding author on reasonable request. The study received no external funding, was approved by the Ethics Committee of Guidong People’s Hospital under approval number GDKY202590, and the authors declare no competing interests.

Even so, the appeal of the approach is hard to overstate. It requires no new hardware, no additional blood draws, and no expensive imaging: the raw material is a routine ECG already recorded for virtually every hospitalized heart failure patient, and the transformation to a vectorcardiogram is a computational step that can be automated in seconds. In an era when deep learning models have shown that ECG voltage data alone can predict mortality, the present work occupies a complementary middle ground—using interpretable, physiologically grounded features extracted from the same inexpensive signal, within a transparent logistic regression framework whose coefficients clinicians can inspect rather than a black box they must trust blindly. Each of the six predictors maps onto a familiar clinical concept: ventricular size, symptom severity, ventricular conduction, and repolarization geometry.

The study team, which also included Hong Chen of the University of Tsukuba, Yi Tan of Guidong People’s Hospital, Lixia Lin of Guangxi University of Chinese Medicine, and Xiaojuan Xu of Tongji University, emphasizes that external multicentre validation is required before any clinical implementation. That caveat is the correct one, and it sets the agenda for the next stage of this line of research. If the 0.934 optimism-corrected AUC survives contact with independent cohorts, heart failure teams could gain a near-zero-cost decision support tool for flagging the roughly four in ten hospitalized patients who face a major cardiovascular event within a year—enabling intensified follow-up, earlier escalation of therapy, and closer surveillance of the patients whose electrical signatures betray a heart in the greatest danger.

Published in Nature Cardiovascular Research, the study investigates the utility of high-sensitivity cardiac troponin I normalized to left ventricular mass for detecting stable coronary artery disease. The idea is deceptively simple: rather than viewing a troponin concentration as an isolated number, researchers relate it to the mass of the left ventricle, the chamber responsible for pumping oxygenated blood through the systemic circulation. The left ventricle is also the portion of the heart most directly exposed to pressure overload and ischemic stress. Its size varies substantially between individuals, and that variation may influence the amount of troponin released into the bloodstream even when the underlying degree of disease is similar. Normalization could therefore provide a more biologically informed measurement than a raw concentration alone.

High-sensitivity cardiac troponin assays have transformed cardiovascular diagnostics because they can detect concentrations far below the limits of earlier tests. Troponin I is a protein found in the contractile apparatus of cardiac muscle cells. When these cells are damaged, even microscopically, fragments of the protein can enter the circulation. In acute coronary syndromes, the pattern is often dramatic: concentrations rise and fall over time, reflecting active injury. Stable coronary artery disease is different. Atherosclerotic plaques may restrict blood flow, and the heart may experience repeated episodes of supply-demand imbalance during exertion, without producing the large, rapidly changing troponin release associated with an infarction. The resulting concentrations can be low but clinically meaningful, creating a measurement challenge precisely where early identification could influence prevention and treatment.

The study’s central contribution is to place that low-level signal in the anatomical context of ventricular mass. A person with a larger left ventricle has more myocardium and potentially more cardiac cells capable of releasing troponin. Conversely, the same measured concentration may represent a different biological burden in a person with a smaller ventricle. Left ventricular hypertrophy, which can develop in response to high blood pressure, aortic valve disease, or other conditions, may further complicate interpretation. If two patients have identical high-sensitivity troponin I values but markedly different ventricular masses, treating those values as equivalent could obscure risk. By expressing troponin relative to left ventricular mass, the investigators test whether the signal becomes more closely linked to the presence of obstructive or otherwise clinically relevant coronary disease.

To establish whether the adjusted marker improves detection, the researchers compared troponin measurements with cardiac structural information and assessments of coronary artery disease. The approach reflects a broader shift in cardiovascular medicine toward combining molecular biomarkers with imaging rather than asking one test to answer every question. High-sensitivity troponin supplies a biochemical readout of myocardial stress or injury, while imaging can quantify the mass of the ventricle and evaluate the coronary arteries. When those data are integrated, clinicians may gain a more precise picture of how much cardiac tissue is exposed to disease and whether the observed biomarker level is disproportionate to the size of the heart. The analysis therefore focuses not only on whether troponin is detectable, but also on whether its interpretation changes when adjusted for a measurable feature of cardiac anatomy.

This distinction matters because stable coronary disease often exists along a continuum rather than as a binary condition. Some patients have plaque without significant blood-flow limitation; others have narrowing that becomes important during exertion; still others have diffuse disease affecting several vessels. Symptoms can be equally variable, ranging from classic exertional chest discomfort to breathlessness, fatigue, or no symptoms at all. Traditional risk factors such as diabetes, smoking, hypertension, high cholesterol, and advancing age remain essential, but they do not reveal how the heart is responding to the disease at a given moment. A biomarker that captures subtle myocardial injury could add a dynamic layer to risk assessment. Normalization to left ventricular mass may help prevent that signal from being diluted by anatomical differences between patients.

The work also illustrates why “normal” laboratory values are not always biologically universal. Reference ranges for high-sensitivity troponin are typically established using selected populations and may be influenced by sex, age, renal function, and coexisting structural heart disease. Troponin concentrations can rise in chronic kidney disease, heart failure, atrial fibrillation, pulmonary disease, and strenuous physical activity, even without an acute coronary blockage. At the same time, a value below a conventional diagnostic threshold does not necessarily mean that the myocardium is entirely unaffected. The investigators’ normalization strategy does not eliminate these confounders, nor is it intended to replace clinical judgment. Instead, it addresses one specific source of variation: the quantity of left ventricular muscle underlying the circulating signal.

The implications extend beyond a new formula. If validated across different populations and clinical settings, a mass-adjusted troponin measurement could support more individualized triage for patients with suspected but stable coronary disease. It might help identify people who would benefit from anatomical imaging, functional stress testing, or more intensive preventive therapy, while reducing unnecessary investigations in those whose low-level troponin signal is proportionate to their cardiac structure and overall risk. Such a tool could be especially useful in patients with left ventricular hypertrophy, where a raw troponin value may be difficult to interpret. However, the test would still need rigorous calibration, standardized imaging protocols, and clear thresholds before it could be integrated into routine care. A promising association is not the same as a universally deployable diagnostic rule.

There are also practical questions that the study brings into sharp focus. Left ventricular mass is usually estimated with echocardiography or cardiac magnetic resonance imaging, and the values can differ according to the imaging method, the mathematical formula used, and the quality of the images. Cardiac magnetic resonance is highly reproducible but less accessible and more expensive than echocardiography. If mass normalization is to become a widely used clinical strategy, researchers will need to determine whether simpler imaging methods provide sufficient accuracy. They must also test the approach in ethnically diverse populations, across a broad range of body sizes and ages, and among people with kidney disease, heart failure, diabetes, and other conditions that influence troponin. Most importantly, future studies will need to show whether the adjusted marker improves patient outcomes, not merely statistical discrimination between groups.

For now, the study offers a compelling example of how cardiovascular diagnostics may evolve from fixed cutoffs toward biologically contextualized measurements. A high-sensitivity troponin result is not simply a number floating in the bloodstream; it is a signal generated by a particular heart, with a particular mass, structure, workload, and disease history. Relating troponin I to left ventricular mass could make that signal easier to interpret in stable coronary artery disease, where conventional testing often operates at the limits of sensitivity. The approach does not turn a blood test into a standalone diagnosis, and it cannot replace imaging or clinical assessment. But by connecting molecular evidence of myocardial injury with the anatomy of the heart itself, Fathieh, Gray, Tang and colleagues point toward a more personalized way to detect coronary disease before it announces itself as an emergency.

Subject of Research: Detection of stable coronary artery disease using high-sensitivity cardiac troponin I normalized to left ventricular mass

Article Title: Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease

Article References: Fathieh, S., Gray, M.P., Tang, O. et al. Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease. Nat Cardiovasc Res 5, 763–776 (2026). https://doi.org/10.1038/s44161-026-00837-z

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00837-z

Keywords: high-sensitivity cardiac troponin I, left ventricular mass, stable coronary artery disease, cardiovascular biomarkers, myocardial injury, cardiac imaging, coronary atherosclerosis, precision medicine